Why docosahexaenoic acid and aspirin supplementation could be useful in women as a primary prevention therapy against Alzheimer's disease?

Ageing Research Reviews

Volumn 10, Issue 1, 2011, Pages 124-131

  Pomponi, Massimo F L ^a   Gambassi, Giovanni ^a   Pomponi, Massimiliano ^a   Di Gioia, Annamaria ^a   Masullo, Carlo ^a  

^a CATHOLIC UNIVERSITY   (Italy)

Author keywords

Alzheimer's disease prevention; Aspirin; Docosahexaenoic acid; Sex specific risk factors

Indexed keywords

ACETYLSALICYLIC ACID; ACYL COENZYME A DESATURASE; ALPHA TOCOPHEROL; AMYLOID BETA PROTEIN; APOLIPOPROTEIN E; BEHENIC ACID; BRAIN DERIVED NEUROTROPHIC FACTOR; CYCLOOXYGENASE 1; CYCLOOXYGENASE 2; DOCOSAHEXAENOIC ACID; ESTROGEN; LEUKOTRIENE; LIPOXIN; MEMBRANE PHOSPHOLIPID; NONSTEROID ANTIINFLAMMATORY AGENT; OMEGA 3 FATTY ACID; OMEGA 6 FATTY ACID; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR AGONIST; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR GAMMA; PROSTAGLANDIN;

AGING; ALZHEIMER DISEASE; ANOVULATION; ANTIINFLAMMATORY ACTIVITY; ANTINEOPLASTIC ACTIVITY; BRAIN NERVE CELL; CARDIOVASCULAR DISEASE; CELL SURVIVAL; COGNITIVE DEFECT; CYTOPATHOLOGY; CYTOTOXICITY; DEMENTIA; DNA RESPONSIVE ELEMENT; DYSLIPIDEMIA; ENDOTHELIAL DYSFUNCTION; FEMALE INFERTILITY; GERIATRIC PATIENT; HIPPOCAMPUS; HUMAN; HYPERANDROGENISM; IMMUNOMODULATION; LIGAND BINDING; LIPID PEROXIDATION; LOW DRUG DOSE; METABOLIC SYNDROME X; MILD COGNITIVE IMPAIRMENT; NEOCORTEX; NERVE DEGENERATION; NEUROPROTECTION; NONHUMAN; OVARY POLYCYSTIC DISEASE; POSTMENOPAUSE; PRIMARY PREVENTION; PROTEIN INDUCTION; REVIEW; RISK FACTOR; SEX DIFFERENCE; SYNAPTOGENESIS;

AGED; ALZHEIMER DISEASE; AMYLOID BETA-PEPTIDES; ANTI-INFLAMMATORY AGENTS, NON-STEROIDAL; APOLIPOPROTEINS E; ASPIRIN; BRAIN-DERIVED NEUROTROPHIC FACTOR; DOCOSAHEXAENOIC ACIDS; FEMALE; HIPPOCAMPUS; HUMANS; NEOCORTEX; NEURAL PATHWAYS; PEROXISOME PROLIFERATOR-ACTIVATED RECEPTORS; RISK FACTORS; WOMEN;

EID: 78650254199     PISSN: 15681637     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.arr.2010.09.003     Document Type: Review

References (88)

1. Abbott N.J. Evidence for bulk flow of brain interstitial fluid: significance for physiology and pathology. Neurochem. Int. 2004, 45:545-552.
2. Alonso-Nanclares L., Gonzalez-Soriano J., Rodriguez J.R., DeFelipe J. Gender differences in human cortical synaptic density. Proc. Natl. Acad. Sci. U.S.A. 2008, 105:14615-14619.
3. Assini A., Cammarata S., Vitali A., Colucci M., Giliberto L., Borghi R., Inglese M.L., Volpe S., Ratto S., Dagna-Bricarelli F., Baldo C., Argusti A., Odetti P., Piccini A., Tabaton M. Plasma levels of amyloid beta-protein 42 are increased in women with mild cognitive impairment. Neurology 2004, 63:828-831.
4. Barbieri M., Bonafè M., Rizzo M.R., Ragno E., Olivieri F., Marchegiani F., Franceschi C., Paolisso G. Gender specific association of genetic variation in peroxisome proliferator-activated receptor (PPAR)gamma-2 with longevity. Exp. Gerontol. 2004, 39(7):1095-1100.
5. Barnes L.L., Wilson R.S., Bienias J.L., Schneider J.A., Evans D.A., Bennett D.A. Sex differences in the clinical manifestations of Alzheimer disease pathology. Arch. Gen. Psychiatry 2005, 62:685-691.
6. Bazan N.G. Omega-3 fatty acids, pro-inflammatory signaling and neuroprotection. Curr. Opin. Clin. Nutr. Metab. Care 2007, 10(2):136-141.
7. Bégin M.E., Ells G., Horrobin D.F. Polyunsaturated fatty acid-induced cytotoxicity against tumor cells and its relationship to lipid peroxidation. J. Natl. Cancer Inst. 1988, 80:188-194.
8. Berzin T.M., Zipser B.D., Rafii M.S., Kuo-Leblanc V., Yancopoulos G.D., Glass D.J., Fallon J.R., Stopa E.G. Agrin and microvascular damage in Alzheimer's disease. Neurobiol. Aging 2000, 21:349-355.
9. Bourgeat P., Chételat G., Villemagne V.L., Fripp J., Raniga P., Pike K., Acosta O., Szoeke C., Ourselin S., Ames D., Ellis K.A., Martins R.N., Masters C.L., Rowe C.C., Salvado O. Beta-amyloid burden in the temporal neocortex is related to hippocampal atrophy in elderly subjects without dementia. Neurology 2010, 74(2):121-127. AIBL Research Group.
10. Bretsky P.M., Buckwalter J.G., Seeman T.E., Miller C.A., Poirier J., Schellenberg G.D., Finch C.E., Henderson V.W. Evidence for an interaction between apolipoprotein E genotype, gender, and Alzheimer disease. Alzheimer Dis. Assoc. Disord. 1999, 13(4):216-221.
11. Burdge G.C. Metabolism of alpha-linolenic acid in humans. Prostaglandins Leukot. Essent. Fatty Acids 2006, 75(3):161-168.
12. Catella-Lawson F., Crofford L.J. Cyclooxygenase inhibition and thrombogenicity. Am. J. Med. 2001, 110(Suppl. 3A):28S-32S.
13. Chiang N., Serhan C.N., Dahlén S.E., Drazen J.M., Hay D.W., Rovati G.E., Shimizu T., Yokomizo T., Brink C. The lipoxin receptor ALX: potent ligand-specific and stereoselective actions in vivo. Pharmacol. Rev. 2006, 58:463-487.
14. Christen Y. Oxidative stress and Alzheimer disease. Am. J. Clin. Nutr. 2000, 71:621S-629S.
15. Cole G.M., Ma Q.L., Frautschy S.A. Omega-3 fatty acids and dementia. Prostaglandins Leukot. Essent. Fatty Acids 2009, 81(2-3):213-221.
16. Craig M.C., Maki P.M., Murphy D.G. The Women's Health Initiative Memory Study: findings and implications for treatment. Lancet Neurol. 2005, 4:190-194.
17. de la Torre J.C. Is Alzheimer's disease a neurodegenerative or a vascular disorder? Data, dogma, and dialectics. Lancet Neurol. 2004, 3:184-190.
18. de Pedro-Cuesta J., Virués-Ortega J., Vega S., Seijo-Martínez M., Saz P., Rodríguez F., Rodríguez-Laso A., Reñé R., de las Heras S.P., Mateos R., Martínez-Martín P., Manubens J.M., Mahillo-Fernandez I., López-Pousa S., Lobo A., Reglà J.L., Gascón J., García F.J., Fernández-Martínez M., Boix R., Bermejo-Pareja F., Bergareche A., Benito-León J., de Arce A., del Barrio J.L. Prevalence of dementia and major dementia subtypes in Spanish populations: a reanalysis of dementia prevalence surveys, 1990-2008. BMC Neurol. 2009, 19:55.
19. Egan M.F., Kojima M., Callicott J.H., Goldberg T.E., Kolachana B.S., Bertolino A., Zaitsev E., Gold B., Goldman D., Dean M., Lu B., Weinberger D.R. The BDNF val66met polymorphism affects activity-dependent secretion of BDNF and human memory and hippocampal function. Cell 2003, 112:257-269.
20. Egan K.M., Lawson J.A., Fries S., Koller B., Rader D.J., Smyth E.M., Fitzgerald G.A. COX-2-derived prostacyclin confers atheroprotection on female mice. Science 2004, 306:1954-1957.
21. Esterbauer H., Schaur R.J., Zollner H. Chemistry and biochemistry of 4-hydroxynonenal, malonaldehyde and related aldehydes. Free Radic. Biol. Med. 1991, 11:81-128.
22. Farrall A.J., Wardlaw J.M. Blood-brain barrier: ageing and microvascular disease - systematic review and meta-analysis. Neurobiol. Aging 2009, 30:337-352.
23. FitzGerald G.A. Cardiovascular pharmacology of nonselective nonsteroidal anti-inflammatory drugs and coxibs: clinical considerations. Am. J. Cardiol. 2002, 89:26D-32D.
24. Fukumoto N., Fujii T., Combarros O., Kamboh M.I., Tsai S.J., Matsushita S., Nacmias B., Comings D.E., Arboleda H., Ingelsson M., Hyman B.T., Akatsu H., Grupe A., Nishimura A.L., Zatz M., Mattila K.M., Rinne J., Goto Y., Asada T., Nakamura S., Kunugi H. Sexually dimorphic effect of the Val66Met polymorphism of BDNF on susceptibility to Alzheimer's disease: new data and meta-analysis. Am. J. Med. Genet. B: Neuropsychiatr. Genet. 2009, (Epub ahead of print).
25. Gao L., Wang J., Sekhar K.R., Yin H., Yared N.F., Schneider S.N., Sasi S., Dalton T.P., Anderson M.E., Chan J.Y., Morrow J.D., Freeman M.L. Novel n-3 fatty acid oxidation products activate Nrf2 by destabilizing the association between Keap1 and Cullin3. J. Biol. Chem. 2007, 282:2529-2537.
26. Giltay E.J., Gooren L.J., Toorians A.W., Katan M.B., Zock P.L. Docosahexaenoic acid concentrations are higher in women than in men because of estrogenic effects. Am. J. Clin. Nutr. 2004, 80(5):1167-1174.
27. Dietary supplementation with n-3 polyunsaturated fatty acids and vitamin E after myocardial infarction: results of the GISSI-Prevenzione trial. Gruppo Italiano per lo Studio della Sopravvivenza nell'Infarto Miocardico. Lancet 1999, 354:447-455. GISSI-Prevenzione Investigators.
28. Gonzalez M.J. Fish oil, lipid peroxidation and mammary tumor growth. J. Am. Coll. Nutr. 1995, 14:325-335.
29. Green R.C., Roberts J.S., Cupples L.A., Relkin N.R., Whitehouse P.J., Brown T., Eckert S.L., Butson M., Sadovnick A.D., Quaid K.A., Chen C., Cook-Deegan R., Farrer L.A. Disclosure of APOE genotype for risk of Alzheimer's disease. N. Engl. J. Med. 2009, 361:245-254. REVEAL Study Group.
30. Hassan A., Hunt B.J., O'Sullivan M., Parmar K., Bamford J.M., Briley D., Brown M.M., Thomas D.J., Markus H.S. Markers of endothelial dysfunction in lacunar infarction and ischaemic leukoaraiosis. Brain 2003, 126(Pt 2):424-432.
31. Hirata-Fukae C., Li H.F., Hoe H.S., Gray A.J., Minami S.S., Hamada K., Niikura T., Hua F., Tsukagoshi-Nagai H., Horikoshi-Sakuraba Y., Mughal M., Rebeck G.W., LaFerla F.M., Mattson M.P., Iwata N., Saido T.C., Klein W.L., Duff K.E., Aisen P.S., Matsuoka Y. Females exhibit more extensive amyloid, but not tau, pathology in an Alzheimer transgenic model. Brain Res. 2008, 1216:92-103.
32. Hock C., Heese K., Hulette C., Rosenberg C., Otten U. Region-specific neurotrophin imbalances in Alzheimer disease: decreased levels of brain-derived neurotrophic factor and increased levels of nerve growth factor in hippocampus and cortical areas. Arch. Neurol. 2000, 57:846-851.
33. Huber J.D., Egleton R.D., Davis T.P. Molecular physiology and pathophysiology of tight junctions in the blood-brain barrier. Trends Neurosci. 2001, 24:719-725.
34. International Diabetes Federation, 2001. The IDF consensus worldwide definition of the metabolic syndrome. (accessed 03.04.06.). http://www.idf.org/webdata/docs/Metabolic_syndrome_definition.pdf.
35. Jiang L.H., Shi Y., Wang L.S., Yang Z.R. The influence of orally administered docosahexaenoic acid on cognitive ability in aged mice. J. Nutr. Biochem. 2009, 20:735-741.
36. Kalaria R.N. The blood-brain barrier and cerebrovascular pathology in Alzheimer's disease. Ann. N.Y. Acad. Sci. 1999, 893:113-125.
37. Katzman R. Education and the prevalence of dementia and Alzheimer's disease. Neurology 1993, 43:13-20.
38. Khan Q.H., Pontefract D.E., Iyengar S., Ye S. Evidence of differing genotypic effects of PPARalpha in women and men. J. Med. Genet. 2004, 41(6):e79.
39. Kitson A.P., Stroud C.K., Stark K.D. Elevated production of docosahexaenoic acid in females: potential molecular mechanisms. Lipids 2010, 45(3):209-224.
40. Kukull W.A., Higdon R., Bowen J.D., McCormick W.C., Teri L., Schellenberg G.D., van Belle G., Jolley L., Larson E.B. Dementia and Alzheimer disease incidence: a prospective cohort study. Arch. Neurol. 2002, 59(11):1737-1746.
41. Lappas M., Permezel M., Holdsworth S.J., Zanoni G., Porta A., Rice G.E. Antiinflammatory effects of the cyclopentenone isoprostane 15-A(2)-IsoP in human gestational tissues. Free Radic. Biol. Med. 2007, 42:1791-1796.
42. Lim G.P., Calon F., Morihara T., Yang F., Teter B., Ubeda O., Salem N., Frautschy S.A., Cole G.M. A diet enriched with the omega-3 fatty acid docosahexaenoic acid reduces amyloid burden in an aged Alzheimer mouse model. J. Neurosci. 2005, 25(12):3032-3040.
43. Liu X., Shibata T., Hisaka S., Kawai Y., Osawa T. DHA hydroperoxides as a potential inducer of neuronal cell death: a mitochondrial dysfunction-mediated pathway. J. Clin. Biochem. Nutr. 2008, 43:26-33.
44. Long E.K., Murphy T.C., Leiphon L.J., Watt J., Morrow J.D., Milne G.L., Howard J.R., Picklo M.J. Trans-4-hydroxy-2-hexenal is a neurotoxic product of docosahexaenoic (22:6; n-3) acid oxidation. J. Neurochem. 2008, 105:714-724.
45. Lukiw W.J., Bazan N.G. Docosahexaenoic acid and the aging brain. J. Nutr. 2008, 138:2510-2514.
46. Marcheselli V.L., Mukherjee P.K., Arita M., Hong S., Antony R., et al. Neuroprotectin D1/protectin D1 stereoselective and specific binding with human retinal pigment epithelial cells and neutrophils. Prostaglandins Leukot. Essent. Fatty Acids 2010, 82(1):27-34.
47. Markesbery W.R. Oxidative stress hypothesis in Alzheimer's disease. Free Radic. Biol. Med. 1997, 23:134-147.
48. Markesbery W.R., Kryscio R.J., Lovell M.A., Morrow J.D. Lipid peroxidation is an early event in the brain in amnestic mild cognitive impairment. Ann. Neurol. 2005, 58:730-735.
49. Melnikova T., Savonenko A., Wang Q., Liang X., Hand T., Wu L., Kaufmann W.E., Vehmas A., Andreasson K.I. Cycloxygenase-2 activity promotes cognitive deficits but not increased amyloid burden in a model of Alzheimer's disease in a sex-dimorphic pattern. Neuroscience 2006, 141:1149-6211.
50. Montine K.S., Reich E., Neely M.D., Sidell K.R., Olson S.J., Markesbery W.R., Montine T.J. Distribution of reducible 4-hydroxynonenal adduct immunoreactivity in Alzheimer disease is associated with APOE genotype. J. Neuropathol. Exp. Neurol. 1998, 57:415-425.
51. Morgan D.R., Dixon L.J., Hanratty C.G., Hamilton P.B., McGrath L.T., Leahey W.J., Johnston G.D., McVeigh G.E. Effects of dietary omega-3 fatty acid supplementation on endothelium-dependent vasodilation in patients with chronic heart failure. Am. J. Cardiol. 2006, 97:547-551.
52. Morris M.C., Evans D.A., Bienias J.L., Tangney C.C., Bennett D.A., Wilson R.S., Aggarwal N., Schneider J. Consumption of fish and n-3 fatty acids and risk of incident Alzheimer disease. Arch. Neurol. 2003, 60:940-946.
53. Musiek E.S., Brooks J.D., Joo M., Brunoldi E., Porta A., Zanoni G., Vidari G., Blackwell T.S., Montine T.J., Milne G.L., McLaughlin B., Morrow J.D. Electrophilic cyclopentenone neuroprostanes are anti-inflammatory mediators formed from the peroxidation of the omega-3 polyunsaturated fatty acid docosahexaenoic acid. J. Biol. Chem. 2008, 283(29):19927-19935.
54. Nakajima K. Pharmacotherapy of mixed dyslipidemia in the metabolic syndrome. Curr. Clin. Pharmacol. 2010.
55. Ott A., Breteler M.M., van Harskamp F., Claus J.J., van der Cammen T.J., Grobbee D.E., Hofman A. Prevalence of Alzheimer's disease and vascular dementia: association with education. The Rotterdam study. BMJ 1995, 310:970-973.
56. Ott A., Breteler M.M., van Harskamp F., Stijnen T., Hofman A. Incidence and risk of dementia. The Rotterdam Study. Am. J. Epidemiol. 1998, 147(6):574-580.
57. Ovbiagele B., Saver J.L. Cerebral white matter hyperintensities on MRI: Current concepts and therapeutic implications. Cerebrovasc. Dis. 2006, 22(2-3):83-90.
58. Patrono C. Aspirin as an antiplatelet drug. N. Engl. J. Med. 1994, 330:1287-1294.
59. Pergola C., Dodt G., Rossi A., Neunhoeffer E., Lawrenz B., Northoff H., Samuelsson B., Rådmark O., Sautebin L. ERK-mediated regulation of leukotriene biosynthesis by androgens: a molecular basis for gender differences in inflammation and asthma. Proc. Natl. Acad. Sci. U.S.A. 2008, 105:19881-19886.
60. Placanica L., Zhu L., Li Y.M. Gender- and age-dependent gamma-secretase activity in mouse brain and its implication in sporadic Alzheimer disease. PLoS One 2009, 4:e5088.
61. Qiu C., Winblad B., Fratiglioni L. The age-dependent relation of blood pressure to cognitive function and dementia. Lancet Neurol. 2005, 4:487-499.
62. Ramanan S., Zhao W., Riddle D.R., Robbins M.E. Role of PPARs in radiation-induced brain injury. PPAR Res. 2010, 2010:234975. (Epub 2009 September 17).
63. Rao J.S., Ertley R.N., Lee H.J., DeMar J.C., Arnold J.T., Rapoport S.I., Bazinet R.P. n-3 polyunsaturated fatty acid deprivation in rats decreases frontal cortex BDNF via a p38 MAPK-dependent mechanism. Mol. Psychiatry 2007, 12:36-46.
64. Razay G., Vreugdenhil A., Wilcock G. The metabolic syndrome and Alzheimer disease. Arch. Neurol. 2007, 64:93-96.
65. Reich E.E., Markesbery W.R., Roberts L.J., 2nd, Swift L.L., Morrow J.D., Montine T.J. Brain regional quantification of F-ring and D-/E-ring isoprostanes and neuroprostanes in Alzheimer's disease. Am. J. Pathol. 2001, 158:293-297.
66. Resnick S.M., Espeland M.A., Jaramillo S.A., Hirsch C., Stefanick M.L., Murray A.M., Ockene J., Davatzikos C. Postmenopausal hormone therapy and regional brain volumes: the WHIMS-MRI Study. Neurology 2009, 72:135-142.
67. Ridker P.M., Cook N.R., Lee I.M., Gordon D., Gaziano J.M., Manson J.E., Hennekens C.H., Buring J.E. A randomized trial of low-dose aspirin in the primary prevention of cardiovascular disease in women. N. Engl. J. Med. 2005, 352:1293-1304.
68. Roberts L.J., Montine T.J., Markesbery W.R., Tapper A.R., Hardy P., Chemtob S., Dettbarn W.D., Morrow J.D. Formation of isoprostane-like compounds (neuroprostanes) in vivo from docosahexaenoic acid. J. Biol. Chem. 1998, 273:13605-13612.
69. Rodondi N., Bauer D.C. Assessing the risk/benefit profile before recommending aspirin for the primary prevention of cardiovascular events. Am. J. Med. 2004, 117:528-530.
70. Ruitenberg A., Ott A., van Swieten J.C., Hofman A., Breteler M.M. Incidence of dementia: does gender make a difference?. Neurobiol. Aging 2001, 22:575-580.
71. Sastre M., Dewachter I., Rossner S., Bogdanovic N., Rosen E., Borghgraef P., Evert B.O., Dumitrescu-Ozimek L., Thal D.R., Landreth G., Walter J., Klockgether T., van Leuven F., Heneka M.T. Nonsteroidal anti-inflammatory drugs repress beta-secretase gene promoter activity by the activation of PPARgamma. PNAS U.S.A. 2006, 103:443-448.
72. Schaefer E.J., Bongard V., Beiser A.S., Lamon-Fava S., Robins S.J., Au R., Tucker K.L., Kyle D.J., Wilson P.W., Wolf P.A. Plasma phosphatidylcholine docosahexaenoic acid content and risk of dementia and Alzheimer disease: The Framingham Heart Study. Arch. Neurol. 2006, 63:1545-1550.
73. Schafer S., Wirths O., Multhaup G., Bayer T.A. Gender dependent APP processing in a transgenic mouse model of Alzheimer's disease. J. Neural Transm. 2007, 114:387-394.
74. Scheff S.W., Price D.A., Schmitt F.A., DeKosky S.T., Mufson E.J. Synaptic alterations in CA1 in mild Alzheimer disease and mild cognitive impairment. Neurology 2007, 68:1501-1508.
75. Serhan C.N., Chiang N. Endogenous pro-resolving and anti-inflammatory lipid mediators: a new pharmacologic genus. Br. J. Pharmacol. 2008, 153(S1):S200-S215.
76. Serhan C.N., Savill J. Resolution of inflammation: the beginning programs the end. Nat. Immunol. 2005, 16:1191-1197.
77. Serhan C.N., Arita M., Hong S., Gotlinger K. Resolvins, docosatrienes, and neuroprotectins, novel omega-3-derived mediators, and their endogenous aspirin-triggered epimers. Lipids 2004, 39(11):1125-1132.
78. Soderberg M., Edlund C., Kristensson K., Dallner G. Fatty acid composition of brain phospholipids in ageing and in Alzheimer's disease. Lipids 1991, 26:421-425.
79. Song W.L., Lawson J.A., Reilly D., Rokach J., Chang C.T., Giasson B., FitzGerald G.A. Neurofurans, novel indices of oxidant stress derived from docosahexaenoic acid. J. Biol. Chem. 2008, 283:6-16.
80. Sprecher H. Metabolism of highly unsaturated n-3 and n-6 fatty acids. Biochim. Biophys. Acta 2000, 1486(2-3):219-231.
81. Stark K.D., Mulvad G., Pedersen H.S., Park E.J., Dewailly E., Holub B.J. Fatty acid compositions of serum phospholipids of postmenopausal women: a comparison between Greenland Inuit and Canadians before and after supplementation with fish oil. Nutrition 2002, 18:627-630.
82. Steenland K., MacNeil J., Vega I., Levey A. Recent trends in Alzheimer disease mortality in the United States, 1999 to 2004. Alzheimer Dis. Assoc. Disord. 2009, 23:165-170.
83. Szekely C.A., Breitner J.C., Fitzpatrick A.L., Rea T.D., Psaty B.M., Kuller L.H., Zandi P.P. NSAID use and dementia risk in the Cardiovascular Health Study: role of APOE and NSAID type. Neurology 2008, 70(1):17-24.
84. Takano T., Clish C.B., Gronert K., Petasis N., Serhan C.N. Neutrophil-mediated changes in vascular permeability are inhibited by topical application of aspirin-triggered 15-epi-lipoxin A4 and novel lipoxin B4 stable analogues. J. Clin. Invest. 1998, 101(4):819-826.
85. Trebble T.M., Arden N.K., Wootton S.A., Calder P.C., Mullee M.A., Fine D.R., Stroud M.A. Fish oil and antioxidants alter the composition and function of circulating mononuclear cells in Crohn disease. Am. J. Clin. Nutr. 2004, 80:1137-1144.
86. Vanhanen M., Koivisto K., Moilanen L., Helkala E.L., Hänninen T., Soininen H., Kervinen K., Kesäniemi Y.A., Laakso M., Kuusisto J. Association of metabolic syndrome with Alzheimer disease: a population-based study. Neurology 2006, 67:843-847.
87. Vasović V., Banić B., Jakovljević V., Tomic Z., Milic-Djordjevic V. Effect of aminophylline on aspirin penetration into the central nervous system in rats. Eur. J. Drug Metab. Pharmacokinet. 2008, 33:23-30.
88. Watson G.S., Cholerton B.A., Reger M.A., Baker L.D., Plymate S.R., Asthana S., Fishel M.A., Kulstad J.J., Green P.S., Cook D.G., Kahn S.E., Keeling M.L., Craft S. Preserved cognition in patients with early Alzheimer disease and amnestic mild cognitive impairment during treatment with rosiglitazone: a preliminary study. Am. J. Geriatr. Psychiatry 2005, 13(11):950-958.